awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35201518-59F7690F-DD8A-413F-BC38-55C7D0B1B037
Q35201518-59F7690F-DD8A-413F-BC38-55C7D0B1B037
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35201518-59F7690F-DD8A-413F-BC38-55C7D0B1B037
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
P2860
Q35201518-59F7690F-DD8A-413F-BC38-55C7D0B1B037
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35201518-59F7690F-DD8A-413F-BC38-55C7D0B1B037
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
47d3789c76428480a408c069b8dbfd6975310e49
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer